How to cite item

Predicting the response to anti-PD1 therapy in metastatic melanoma

   
@article{TCR9534,
	author = {Lucie Heinzerling and Michael Constantin Kirchberger and Lisa Walter and Gerold Schuler},
	title = {Predicting the response to anti-PD1 therapy in metastatic melanoma},
	journal = {Translational Cancer Research},
	volume = {5},
	number = {Suppl 3},
	year = {2016},
	keywords = {},
	abstract = {Checkpoint inhibitor therapy has proven effective in metastatic melanoma and a range of other tumor entities including non-small cell lung carcinoma, Hodgkin lymphoma and renal cell carcinoma. Despite the impressive and often durable induction of tumor regression, 60–70% of patients with metastatic melanoma do not respond to single agent therapy with the anti-programmed death (PD)-1 antibodies pembrolizumab (1) or nivolumab (2). Combination treatment with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 antibody, has resulted in higher response rates of 58%; however, this benefit comes with around 55% grade 3/4 side effects (2).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/9534}
}